The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Pergamid     N,N-bis(2-chloroethyl)-4- hydroperoxy-2-oxo...

Synonyms: PERFOSFAMIDE, CHEMBL61511, CCRIS 2541, AG-F-40662, ASTA 6496, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ASTA 6496


High impact information on ASTA 6496


Chemical compound and disease context of ASTA 6496


Biological context of ASTA 6496


Anatomical context of ASTA 6496


Associations of ASTA 6496 with other chemical compounds


Gene context of ASTA 6496


Analytical, diagnostic and therapeutic context of ASTA 6496


  1. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. Yeager, A.M., Kaizer, H., Santos, G.W., Saral, R., Colvin, O.M., Stuart, R.K., Braine, H.G., Burke, P.J., Ambinder, R.F., Burns, W.H. N. Engl. J. Med. (1986) [Pubmed]
  2. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Shpall, E.J., Stemmer, S.M., Hami, L., Franklin, W.A., Shaw, L., Bonner, H.S., Bearman, S.I., Peters, W.P., Bast, R.C., McCulloch, W. Blood (1994) [Pubmed]
  3. Differential effect of 4-hydroperoxycyclophosphamide and antimyeloid monoclonal antibodies on T and natural killer cells during bone marrow purging. Zhong, R.K., Donnenberg, A.D., Rubin, J., Ball, E.D. Blood (1994) [Pubmed]
  4. Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. Uckun, F.M., Gajl-Peczalska, K., Meyers, D.E., Ramsay, N.C., Kersey, J.H., Colvin, M., Vallera, D.A. Blood (1987) [Pubmed]
  5. In vitro restoration of polyclonal hematopoiesis in a chronic myelogenous leukemia after in vitro treatment with 4-hydroperoxycyclophosphamide. Degliantoni, G., Mangoni, L., Rizzoli, V. Blood (1985) [Pubmed]
  6. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. St Croix, B., Flørenes, V.A., Rak, J.W., Flanagan, M., Bhattacharya, N., Slingerland, J.M., Kerbel, R.S. Nat. Med. (1996) [Pubmed]
  7. In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration. Ozer, H., Cowens, J.W., Colvin, M., Nussbaum-Blumenson, A., Sheedy, D. J. Exp. Med. (1982) [Pubmed]
  8. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. Comabella, M., Balashov, K., Issazadeh, S., Smith, D., Weiner, H.L., Khoury, S.J. J. Clin. Invest. (1998) [Pubmed]
  9. Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. Brandt, J., Baird, N., Lu, L., Srour, E., Hoffman, R. J. Clin. Invest. (1988) [Pubmed]
  10. Cytotoxicity of 4-hydroperoxycyclophosphamide for the blast progenitors of acute myeloblastic leukemia. Nara, N., Suzuki, T., Yamashita, Y., Murohashi, I., Aoki, N. Cancer Res. (1988) [Pubmed]
  11. Phase I study of combination drug purging for autologous bone marrow transplantation. Rowley, S.D., Miller, C.B., Piantadosi, S., Davis, J.M., Santos, G.W., Jones, R.J. J. Clin. Oncol. (1991) [Pubmed]
  12. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Yamauchi, T., Nowak, B.J., Keating, M.J., Plunkett, W. Clin. Cancer Res. (2001) [Pubmed]
  13. Increased rate of glutathione synthesis from cystine in drug-resistant MCF-7 cells. Gamcsik, M.P., Dubay, G.R., Cox, B.R. Biochem. Pharmacol. (2002) [Pubmed]
  14. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Chen, G., Waxman, D.J. Biochem. Pharmacol. (1995) [Pubmed]
  15. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. DeLeve, L.D. Hepatology (1996) [Pubmed]
  16. The role of p53 and cell death by apoptosis and necrosis in 4-hydroperoxycyclophosphamide-induced limb malformations. Moallem, S.A., Hales, B.F. Development (1998) [Pubmed]
  17. Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease. Geller, R.B., Vogelsang, G.B., Wingard, J.R., Yeager, A.M., Burns, W.H., Santos, G.W., Saral, R. J. Clin. Oncol. (1988) [Pubmed]
  18. Intrathecal 4-hydroperoxycyclophosphamide: neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosis. Phillips, P.C., Than, T.T., Cork, L.C., Hilton, J., Carson, B.S., Colvin, O.M., Grochow, L.B. Cancer Res. (1992) [Pubmed]
  19. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Kasahara, K., Fujiwara, Y., Nishio, K., Ohmori, T., Sugimoto, Y., Komiya, K., Matsuda, T., Saijo, N. Cancer Res. (1991) [Pubmed]
  20. CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Rowley, S.D., Zuehlsdorf, M., Braine, H.G., Colvin, O.M., Davis, J., Jones, R.J., Saral, R., Sensenbrenner, L.L., Yeager, A., Santos, G.W. Blood (1987) [Pubmed]
  21. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Rowley, S.D., Jones, R.J., Piantadosi, S., Braine, H.G., Colvin, O.M., Davis, J., Saral, R., Sharkis, S., Wingard, J., Yeager, A.M. Blood (1989) [Pubmed]
  22. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Teicher, B.A., Holden, S.A., Cucchi, C.A., Cathcart, K.N., Korbut, T.T., Flatow, J.L., Frei, E. Cancer Res. (1988) [Pubmed]
  23. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer. Kennedy, M.J., Davis, J., Passos-Coelho, J., Noga, S.J., Huelskamp, A.M., Ohly, K., Davidson, N.E. Cancer Res. (1993) [Pubmed]
  24. In vitro effects of 4-hydroperoxycyclophosphamide on the morphology and function of human peripheral blood mononuclear phagocytic cells (macrophages). Jason, M., Andrews, B.S., Colvin, M., Friou, G.J. Cancer Res. (1984) [Pubmed]
  25. Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay. Hida, T., Ueda, R., Takahashi, T., Watanabe, H., Kato, T., Suyama, M., Sugiura, T., Ariyoshi, Y., Takahashi, T. Cancer Res. (1989) [Pubmed]
  26. Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Frost, P., Abbruzzese, J.L., Hunt, B., Lee, D., Ellis, M. Cancer Res. (1990) [Pubmed]
  27. Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro. Sahovic, E.A., Colvin, M., Hilton, J., Ogawa, M. Cancer Res. (1988) [Pubmed]
  28. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines. Kohn, F.R., Landkamer, G.J., Manthey, C.L., Ramsay, N.K., Sladek, N.E. Cancer Res. (1987) [Pubmed]
  29. Experimental chemotherapy of human medulloblastoma with classical alkylators. Friedman, H.S., Colvin, O.M., Ludeman, S.M., Schold, S.C., Boyd, V.L., Mulhbaier, L.H., Bigner, D.D. Cancer Res. (1986) [Pubmed]
  30. The effects of tumor necrosis factor-alpha on early human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide. Moreb, J., Zucali, J.R., Rueth, S. Blood (1990) [Pubmed]
  31. Retroviral vector-mediated gene transfer into primitive human hematopoietic progenitor cells: effects of mast cell growth factor (MGF) combined with other cytokines. Nolta, J.A., Crooks, G.M., Overell, R.W., Williams, D.E., Kohn, D.B. Exp. Hematol. (1992) [Pubmed]
  32. Transglutaminase and clusterin induction during normal and abnormal limb development in the mouse. Adel Moallem, S., Hales, B.F. Biol. Reprod. (1996) [Pubmed]
  33. Teratogen-induced activation of caspase-9 and the mitochondrial apoptotic pathway in early postimplantation mouse embryos. Little, S.A., Mirkes, P.E. Toxicol. Appl. Pharmacol. (2002) [Pubmed]
  34. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purged marrows for acute nonlymphocytic leukemia in late remission or early relapse. Rosenfeld, C., Shadduck, R.K., Przepiorka, D., Mangan, K.F., Colvin, M. Blood (1989) [Pubmed]
  35. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. Uckun, F.M., Kersey, J.H., Haake, R., Weisdorf, D., Ramsay, N.K. Blood (1992) [Pubmed]
  36. Hematopoietic precursors resistant to treatment with 4-hydroperoxycyclophosphamide: requirement for an interaction with marrow stroma in addition to hematopoietic growth factors for maximal generation of colony-forming activity. Rowley, S.D., Brashem-Stein, C., Andrews, R., Bernstein, I.D. Blood (1993) [Pubmed]
  37. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Anderson, I.C., Shpall, E.J., Leslie, D.S., Nustad, K., Ugelstad, J., Peters, W.P., Bast, R.C. Cancer Res. (1989) [Pubmed]
WikiGenes - Universities